Business Wire

ESI-GROUP

22.9.2021 14:26:12 CEST | Business Wire | Press release

Share
ESI Group: EMPHYSIS – The Missing Link Between Digital Simulation and Embedded Software

Regulatory News:

ESI Group (Paris:ESI):

The research project EMPHYSIS led by Bosch has delivered the new “eFMI standard” for model exchange to accelerate the model-based development of embedded software. On the 15th of September, this international collaborative project gathering 25 industrial and academic partners from different fields (like automotive and information technologies) situated in Belgium, Canada, France, Germany, and Sweden received the ITEA Award of Excellence for this unique achievement.

Better code with less effort through “eFMI” - the new model-exchange standard for embedded devices

When developing a new function, many engineers learn the hard way that their outstanding knowledge about the physics of their products is not enough by far to develop a function for an embedded target, due to the demanding requirements of safety-critical software, weak CPU magnitude and less memory than expected. While this might result in a never-to-be-realised excellent initial idea of operating and controlling their product in a much smarter way, at the same time it reveals the need for a link between digital simulation of physical processes and embedded software.

The aim of the EMPHYSIS project (Embedded Systems with Physical Models in the Production Code Software), led by Bosch, was to jointly come up with a new open standard that lays the foundation to develop new innovative tools. This that allows model-based functions to be realized directly in embedded software with better code and less effort. For this purpose, the project carried forward the idea of the very successful Functional Mock-up Interface (FMI) model exchange standard for simulation to develop FMI for embedded systems - the new “eFMI standard”. This enables a wide variety of advanced model-based approaches for control and diagnosis, such as solving a set of differential equations to compute a signal instead of measuring it via a sensor. By allowing a hardware sensor to be replaced with a piece of software, we significantly reduce the total cost.

« The EMPHYSIS project has achieved several outstanding results such as the automatic generation of efficient code for embedded devices. It shows the power of collaborative research projects to drive the adoption of a new standard and to generate significant productivity gains for the industry. »

– Jean-François Lavignon, ITEA Vice-chairman

The technical deep dive and benefits

Technically speaking, eFMI is innovative in that it provides a target-independent intermediate format defined by an entirely new language, the Guarded Algorithmic Language for Embedded Control: GALEC. This new programming language is able to guarantee that an algorithm described in this language can be translated into code that has:

  • static worst-case execution time;
  • static a-priori known memory demand; and
  • a statically proven absence of illegal memory access.

In other words: code that satisfies the hard requirements of automotive safety-critical embedded software, which also makes it applicable to many more, less restricted domains like robotics, industrial applications and consumer goods.

With eFMI and GALEC it is now possible to capture the computational essence of a model in a target-independent form that is a solid foundation for any code generator to produce highly optimised code for arbitrary runtime environments and software architectures. All this is cast into a traceable, extendable and verifiable container architecture that goes far beyond a simple exchange format.

The eFMI workflow allows developers to model a system on a higher level of abstraction, starting with a reusable, high-level, component-oriented and physically structured model. The tooling kit then automatically transforms this into a solution which can be better integrated into software.

The main benefits of this solution and the associated eFMI workflow are:

  • accelerating development time;
  • better use of domain experts by separating the concerns of physical modelling and embedded implementation;
  • overcoming vendor lock-in through eFMI being published as an open standard on GitHub; and
  • enabling new ways of OEM supplier collaborations.

Continuous success

An OEM Advisory Board has been established to gather additional requirements, input and use-cases and further disseminate the project’s results, helping to secure uptake and future innovations in new domains.

On 22 March 2021, right after the project’s end, the non-profit Modelica Association officially approved a new project under its umbrella to further develop, standardize and promote eFMI. With Robert Bosch GmbH, Dassault Systèmes, DLR Institute of System Dynamics and Control, dSPACE, ESI Group, ETAS GmbH and Modelon AB as initial members of the steering committee and Mercedes-Benz AG having joined recently, the first official release of eFMI 1.0 is targeted within 2021. Having developed 14 tools within EMPHYSIS, eFMI already has a broad foundation even before its official release.

« What makes us proud as a team is the fact that this success has been recognized not only by our business partners and the OEM Advisory Board representing the voice of the customer, but also by the ITEA organization.»

– Oliver Lenord, Research Engineer at the Model-based Systems Engineering department at Robert Bosch

For society as a whole, EMPHYSIS’ better software translates into safer and more efficient vehicles which are able to keep pace with customer demands and help tackle climate issues in the longer term. For the time being, however, the project’s message is clear: by taking full advantage of an equation-based, component-oriented modelling language with a good library, 90% gains can be made in productivity of model-based function development.

EMPHYSIS project partners

Belgium

  • Dana Belgium
  • Siemens Industry Software NV
  • University of Antwerp NEXOR

Canada

  • Maplesoft

France

  • CEA
  • Dassault Systemes SE
  • FH Electronics
  • Institut Polytechnique de Grenoble
  • OSE Engineering
  • Renault SAS
  • Siemens Industry Software SAS
  • SOBEN

Germany

  • AbsInt Angewandte Informatik GmbH
  • Deutsches Zentrum für Luft- und Raumfahrt (DLR) System Dynamics and Control
  • dSPACE GmbH
  • Elektronische Fahrwerksysteme GmbH
  • ESI ITI GmbH, part of ESI Group
  • ETAS GmbH
  • PIKETEC
  • Robert Bosch GmbH

Sweden

  • Dassault Systèmes AB
  • Linköping University
  • Modelon AB
  • RISE - Research institutes of Sweden SICS East
  • Volvo Personvagnar AB

About ITEA

ITEA is the Eureka Cluster for software innovation, enabling a large international community to collaborate in funded projects that turn innovative ideas into new businesses, jobs, economic growth and benefits for society. https://itea4.org

About ESI Group

Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval, energy and heavy industry, ESI is present in more than 20 countries, employs 1200 people around the world and reported 2020 sales of €132.6 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.

For further information: https://www.esi-group.com/fr .

Follow ESI

http://www.esi-group.com/linkedin
http://www.esi-group.com/facebook
http://www.esi-group.com/twitter
http://www.esi-group.com/youtube

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release

Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi

Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme

Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release

Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting

Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release

On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-

Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release

Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye